High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma Meeting Abstract

  

Authors:	Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; Batlevi, C. L.; Hamlin, P. A.; Straus, D. J.; Rodriguez-Rivera, I.; Owens, C.; Caron, P.; Colbourn, D. S.; Intlekofer, A. M.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Palomba, M. L.; Noy, A.; Matasar, M. J.; Vardhana, S.; von Keudell, G. R.; Yahalom, J.; Younes, A.; Zelenetz, A. D.; Moskowitz, C. H.
Abstract Title:	High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
Meeting Title:	61st Annual Meeting and Exposition of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	134
Issue:	Suppl. 1
Meeting Dates:	2019 Dec 7-10
Meeting Location:	Orlando, FL
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2019-11-13
Language:	English
ACCESSION:	WOS:000577160406218
DOI:	10.1182/blood-2019-127575
PROVIDER:	wos
Notes:	Meeting Abstract: 2837 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/175720